世卫组织将中国科兴新冠疫苗列入“紧急使用清单” -- 第二个中国疫苗

Hard Worker

知名会员
注册
2012-08-31
消息
3,260
荣誉分数
997
声望点数
173

世卫组织将中国科兴新冠疫苗列入“紧急使用清单”

当地时间6月1日,世卫组织宣布将中国科兴新冠疫苗列入“紧急使用清单”。(总台记者 朱赫)
 

向问天

日月神教光明左使
VIP
注册
2012-09-04
消息
60,455
荣誉分数
10,996
声望点数
1,273

Hard Worker

知名会员
注册
2012-08-31
消息
3,260
荣誉分数
997
声望点数
173
又拖了一个月。
WHO是很不情愿啊
拖时间对谁不利?呵呵,一群傻逼。国药和科兴到年底的产量超过50亿,明年超过80亿,好买卖。
 

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
24,630
荣誉分数
6,093
声望点数
373
莫德纳正在寻求FDA full approval。

2 hr 16 min ago

Moderna seeks full FDA approval for its Covid-19 vaccine​

From CNN’s Michael Nedelman
A healthcare worker administers a dose of Moderna's Covid-19 vaccine at the American Museum of Natural History in New York on April 30.
A healthcare worker administers a dose of Moderna's Covid-19 vaccine at the American Museum of Natural History in New York on April 30. Gabby Jones/Bloomberg/Getty Images

Moderna announced it has begun applying for full approval for its Covid-19 vaccine in people ages 18 and up.

The company says it will continue to submit trial data “on a rolling basis over the coming weeks with a request for a Priority Review.” A priority review asks the US Food and Drug Administration to take action within six months, compared to the 10 months designated under standard review.

“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stéphane Bancel said in a statement Tuesday. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.”

Since December, Moderna’s two-shot vaccine has been distributed under an emergency use authorization for people ages 18 and up. In April, the company announced its vaccine maintained over 90% efficacy six months out – the amount of follow-up time needed to apply for FDA approval.

Moderna is the second company to seek such approval in the US. Last month, Pfizer announced it was initiating its own application for people ages 16 and up, following an April announcement that its clinical trials showed over 91% efficacy after six months. Experts say they expect this protection will last much longer, to be confirmed as more data come in.

Being granted FDA approval may motivate some vaccine-hesitant people to roll up their sleeves, according to research released Friday by the Kaiser Family Foundation.

Both Pfizer and Moderna are also studying their vaccines in children as young as 6 months. Last month, the FDA granted Pfizer’s vaccine an emergency use authorization for children 12 to 15.
 

向问天

日月神教光明左使
VIP
注册
2012-09-04
消息
60,455
荣誉分数
10,996
声望点数
1,273
拖时间对谁不利?呵呵,一群傻逼。国药和科兴到年底的产量超过50亿,明年超过80亿,好买卖。


还有第3针第4针,想不发财都难。
 
顶部